As markets navigate a new year, analysts are eyeing potential outperformers. Amazon, BeOne Medicines, and Enterprise Products Partners emerge as compelling picks, each backed by distinct catalysts from AI to biotech breakthroughs.
Israel is set to partially reopen the Rafah border crossing with Egypt, allowing limited pedestrian movement for Palestinians. The move, a condition of the U.S.-brokered ceasefire, comes amid ongoing tensions and a continued ban on foreign journalists.
Boston Scientific's latest earnings beat and raised guidance, fueled by strong demand for its electrophysiology devices, signal a strategic shift. The company is navigating tariff pressures while expanding margins, with major acquisitions poised to reshape its long-term profile.
Glaukos Corporation secures a significant FDA nod allowing repeated administration of its sustained-release iDose TR implant, broadening treatment options for patients with glaucoma and potentially reshaping long-term care paradigms.
Certified financial planner and popular financial educator Kevin Lum outlines a crucial mindset shift for those nearing or in retirement, urging them to move beyond accumulation and toward purposeful living.
While the FTSE 100 grapples with global headwinds, a segment of smaller UK-listed companies presents distinct opportunities. We examine three firms, each with a market capitalisation over £90 million, that combine financial resilience with specific growth catalysts.
Cardiac monitoring specialist iRhythm has finalized a significant corporate restructuring, creating a new parent company to serve as its publicly listed entity on Nasdaq. The move is seen as a strategic step to streamline governance and provide operational flexibility as the company expands its AI-driven health platform.
Shares of insulin pump maker Tandem Diabetes Care have plummeted over 80% in five years, trading near $20. A deep dive into valuation metrics suggests the stock may now be modestly undervalued, but significant risks and competitive pressures remain.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
As Europe's markets navigate a fragile recovery, investors are turning to dividend-paying stocks for income and resilience. We examine three companies offering attractive yields, weighing their potential against underlying financial risks.
Takeda Pharmaceutical's (TSE:4502) recent share price rally has ignited a debate among investors. With the stock closing at ¥5,242, analysts are divided on its true worth, presenting a complex picture of fair value signals and future growth prospects.
CONMED's latest earnings reveal a strategic pivot towards higher-growth surgical platforms, moving away from slower gastroenterology lines. While sales climbed, profitability softened, setting the stage for a crucial transition year as the market weighs the company's reset valuation against its ambitious 2026 roadmap.
Fresenius SE & Co. KGaA (ETR:FRE) faces a challenging period as its stock declines, with a key profitability metric and a high dividend payout strategy raising questions about its near-term growth prospects.
Ryman Hospitality Properties (RHP) presents a complex picture for investors. While boasting a strong 54% total return over five years, recent performance has been mixed, raising questions about whether its current share price of around $94.70 truly reflects its underlying value or future challenges.
The vital Rafah border crossing between Egypt and the Gaza Strip reopened Sunday for limited passenger traffic, marking a significant shift after more than two years of closure. The move, part of a ceasefire deal, initiates a tightly controlled process allowing medical evacuations and returns, though humanitarian aid flow remains uncertain.
After nearly two years of near-total closure, the Rafah border crossing between Gaza and Egypt is set to reopen under a coordinated pilot operation. The move, a key element of international ceasefire efforts, will initially allow hundreds of critically ill patients and their families to seek medical care abroad.
House Speaker Mike Johnson expressed confidence that Republicans have the votes to pass a stopgap funding bill by Tuesday, aiming to end a partial government shutdown triggered over the weekend amid ongoing immigration policy disputes.
The Israeli government has ordered Médecins Sans Frontières (MSF) to cease operations in Gaza by the end of February, citing the aid group's refusal to hand over details of its Palestinian staff—a move critics decry as a dangerous politicization of humanitarian aid.
Israel announces a limited, security-heavy reopening of Gaza's Rafah crossing with Egypt, allowing some medical evacuations while concerns mount over aid access and the safety of returnees.
As Costa Ricans cast their ballots this Sunday, the election is defined by unprecedented security fears, economic inequality, and widespread political disenchantment, challenging the country's long-held identity as a peaceful and stable democracy.
